Mitapivat Phase 3 Trial for Pediatric PKD Completes Primary Study

On May 3, 2024, the Phase 3 study evaluating mitapivat for pediatric pyruvate kinase deficiency (PKD) completed its primary study period. The trial, identified as NCT05144256, enrolled 49 pediatric participants.

Background

Mitapivat, also known by its aliases Aqvesme and Pyrukynd, is being investigated for its potential in treating pediatric pyruvate kinase deficiency (PKD) and pediatric hemolytic anemia. PKD is a rare, inherited metabolic disorder that affects red blood cells, leading to chronic hemolytic anemia.

Trial design

The Phase 3 study, NCT05144256, titled "A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Regularly Transfused, Followed by a 5-Year Extension Period," enrolled 49 participants. The study is designed to assess the efficacy and safety of mitapivat compared with a mitapivat-matching placebo in pediatric participants with pyruvate kinase deficiency who regularly receive blood transfusions. Participants were randomized in a 2:1 ratio to receive either mitapivat or placebo. Randomization was stratified by age, specifically 1 to < 6 years, 6 to < 12 years, and 12 to < 18 years, as well as by splenectomy status. Dosing for participants was determined based on their age and weight during a double-blind period, which included an 8-week dose titration period.

What this means

The primary completion of the Phase 3 ACTIVATE-KidsT study signifies that the main data collection phase for its primary endpoints has concluded. While this marks a significant milestone in the trial's progression, no specific efficacy or safety results from this study have been released yet. The study aims to provide crucial data on mitapivat as a potential treatment option for pediatric patients with pyruvate kinase deficiency who require regular blood transfusions. Clinicians and patient advocates will await the release of these results to understand the potential impact of mitapivat in this vulnerable population.

Source

Information regarding the primary completion of this trial was sourced from ClinicalTrials.gov, a public database of clinical studies. The update for study NCT05144256, "A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Regularly Transfused, Followed by a 5-Year Extension Period", was posted on 2024-05-03 on clinicaltrials.gov.